Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor
in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after
treatment of an aromatase inhibitor.